Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.

摘要: In this section, many different issues are written about by authors from the UK, France, Netherlands, USA and Denmark, respectively. Topics covered botulinum toxin in drug-resistant neurogenic detrusor overactivity spinal cord injury, dutasteride BPH, effect of childbirth on bothersome LUTS, female urethral strictures, a new bulking agent treating stress urinary incontinence. OBJECTIVES To assess, prospective study, whether toxin-type A (BTX-A) injected into muscle, can be used as day-case treatment for (NDO) patients with injury (SCI). PATIENTS AND METHODS BTX-A (Dysport, Ipsen, Luxembourg; 1000 units) was cystoscopically muscle 37 NDO SCI, procedure. The maximum cystometric capacity (MCC), pressure (MDP), NDO, continence, anticholinergic requirement were outcome variables. International Consultation Incontinence questionnaire (ICIQ) to assess patient’s quality life before after BTX-A injection. RESULTS The mean follow-up 7 months. MCC increased 259 to 522 mL, MDP decreased 54 24 cmH2O. abolished 82% 76% patients, all, 86% able stop or reduce anticholinergics, similar proportion scoring favourably ICIQ. duration improvement 9 months. CONCLUSIONS Injection is an effective that bridges gap between oral invasive surgical SCI.